Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/175067
Title: | Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 |
Author: | Barbui, Tiziano Stefano, Valerio De Álvarez Larrán, Alberto Iurlo, Alessandra Masciulli, Arianna Carobbio, Alessandra Ghirardi, Arianna Ferrari, Alberto Cancelli, Valeria Elli, Elena Maria Andrade Campos, Marcio Miguel Gasior Kabat, Mercedes Kiladjian, Jean-Jacques Palandri, Francesca Benevolo, Giulia Garcia Gutierrez, Valentin Fox, Maria Laura Foncillas, Maria Angeles Morcillo, Carmen Montoya Rumi, Elisa Osorio, Santiago Papadopoulos, Petros Bonifacio, Massimiliano Quiroz Cervantes, Keina Susana Serrano, Miguel Sagues Carreño Tarragona, Gonzalo Sobas, Marta Anna Lunghi, Francesca Patriarca, Andrea Elorza, Begoña Navas Angona, Anna Mazo, Elena Magro Koschmieder, Steffen Carli, Giuseppe Cuevas, Beatriz Hernandez Boluda, Juan Carlos Abadia, Emma Lopez Xicoy Cirici, Blanca Guglielmelli, Paola Garrote i Ordeig, Marta Cattaneo, Daniele Daffini, Rosa Cavalca, Fabrizio Bellosillo, Beatriz Benajiba, Lina Curto Garcia, Natalia Bellini, Marta Betti, Silvia Harrison, Claire Rambaldi, Alessandro Vannucchi, Alessandro Maria |
Keywords: | Leucèmia mieloide Trombosi COVID-19 Myeloid leukemia Thrombosis COVID-19 |
Issue Date: | 1-Feb-2021 |
Publisher: | Springer Nature |
Abstract: | In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41408-021-00417-3 |
It is part of: | Blood Cancer Journal, 2021, vol. 11 |
URI: | https://hdl.handle.net/2445/175067 |
Related resource: | https://doi.org/10.1038/s41408-021-00417-3 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41408-021-00417-3.pdf | 1.38 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License